股票行情快报：心脉医疗（688016）8月12日主力资金净卖出3803.64万元

Core Viewpoint - The stock of Xinmai Medical (688016) has shown a slight increase of 1.55% as of August 12, 2025, with significant net inflows from retail investors despite outflows from institutional and speculative funds [1][2]. Financial Performance - Xinmai Medical reported a total market capitalization of 14.791 billion yuan and a net profit of 130 million yuan, which represents a year-on-year decline of 29.66% [3]. - The company's main revenue for Q1 2025 was 332 million yuan, down 7.23% year-on-year, with a gross margin of 69.61% [3]. - The company has a debt ratio of 13.0% and reported investment income of 4.2262 million yuan [3]. Market Position - Xinmai Medical's price-to-earnings ratio (P/E) stands at 28.52, significantly lower than the industry average of 69.5, indicating a potentially undervalued position [3]. - The company ranks 18th in net profit within the medical device industry, which has an average net profit of 79.2736 million yuan [3]. Investment Sentiment - Over the past 90 days, 7 institutions have rated the stock, with 6 buy ratings and 1 hold rating, suggesting a generally positive outlook [4]. - The average target price set by institutions for the stock is 122.06 yuan [4]. Trading Activity - On August 12, 2025, the stock had a trading volume of 41,900 hands and a total transaction value of 507 million yuan [1]. - The net outflow of institutional funds was 38.0364 million yuan, while retail investors saw a net inflow of 39.7165 million yuan, indicating strong retail interest [1][2].